Authorized purpose: Clarius Prostate AI provides semi-automatic measurements of prostate volume from ultrasound data acquired by the Clarius Ultrasound Scanner.
Clinical role
Assistive ultrasound acquisition and interpretation support through segmentation, caliper placement, and semi-automatic prostate-volume measurement.
Images and patients
Ultrasound · Prostate
Key limitation
Keep in mind: Limited to adult male patients, B-mode use, and the named Clarius scanner and transducer configurations. It is not standalone software, does not replace clinical decision-making, and the user must confirm measurements using standard practice and clinical judgment.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Clarius Prostate AI provides semi-automatic measurements of prostate volume from ultrasound data acquired by the Clarius Ultrasound Scanner.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Prostate Input: B-mode prostate ultrasound data acquired with Clarius C3 HD3 or EC7 HD3 curvilinear or endo-cavitary scanners through the Clarius App.
Who uses it?Intended users: Healthcare professionals trained and qualified in ultrasound.
What does the software produce?Output: Automatic prostate length, width, and height measurements, corresponding-view detection, segmentation, adjustable caliper placement, and calculated prostate volume.
What is its most important limitation?Key limitation: Limited to adult male patients, B-mode use, and the named Clarius scanner and transducer configurations. It is not standalone software, does not replace clinical decision-making, and the user must confirm measurements using standard practice and clinical judgment.
Clinical takeaway. Clinical role: Clarius Prostate AI provides semi-automatic measurements of prostate volume from ultrasound data acquired by the Clarius Ultrasound Scanner.
Evidence takeaway. Evidence from the reviewed source record: The FDA summary reports a retrospective, multicenter clinical-verification study of 139 male subjects, separate from model training and tuning. It reports 95% view-prediction accuracy and ICC values of 0.87 for endo-cavitary and 0.67 for curvilinear probes. These are manufacturer regulatory-study results, not independent clinical-outcome evidence.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Clarius Prostate AI provides semi-automatic measurements of prostate volume from ultrasound data acquired by the Clarius Ultrasound Scanner.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Limited to adult male patients, B-mode use, and the named Clarius scanner and transducer configurations. It is not standalone software, does not replace clinical decision-making, and the user must confirm measurements using standard practice and clinical judgment.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The FDA summary reports a retrospective, multicenter clinical-verification study of 139 male subjects, separate from model training and tuning. It reports 95% view-prediction accuracy and ICC values of 0.87 for endo-cavitary and 0.67 for curvilinear probes. These are manufacturer regulatory-study results, not independent clinical-outcome evidence.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA summary reports a retrospective, multicenter clinical-verification study of 139 male subjects, separate from model training and tuning. It reports 95% view-prediction accuracy and ICC values of 0.87 for endo-cavitary and 0.67 for curvilinear probes. These are manufacturer regulatory-study results, not independent clinical-outcome evidence.
FDA source
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Clarius Prostate AI regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K243853
Samplen=139
IndependenceIndependence not established
K243853
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: B-mode prostate ultrasound data acquired with Clarius C3 HD3 or EC7 HD3 curvilinear or endo-cavitary scanners through the Clarius App.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Clarius Prostate AI is integrated into the Clarius App for iOS and Android and operates with the named Clarius Ultrasound Scanner configurations; it is not standalone software. Local downstream interface compatibility is not established by the FDA packet.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Clarius Prostate AI as an algorithm integrated into the Clarius App software for iOS and Android, as part of the Clarius Ultrasound Scanner system, and not a stand-alone software device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Clarius Prostate AI is a machine learning algorithm that is integrated into the Clarius App software as part of the comprehensive Clarius Ultrasound Scanner system" … "Clarius Prostate AI is integrated into the Clarius App software, which is compatible with iOS and Android operating systems". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Automatic prostate length, width, and height measurements, corresponding-view detection, segmentation, adjustable caliper placement, and calculated prostate volume.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Clarius Prostate AI as an algorithm integrated into the Clarius App software for iOS and Android, as part of the Clarius Ultrasound Scanner system, and not a stand-alone software device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Clarius Prostate AI is a machine learning algorithm that is integrated into the Clarius App software as part of the comprehensive Clarius Ultrasound Scanner system" … "Clarius Prostate AI is integrated into the Clarius App software, which is compatible with iOS and Android operating systems". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Clarius Prostate AI is integrated into the Clarius App for iOS and Android and operates with the named Clarius Ultrasound Scanner configurations; it is not standalone software. Local downstream interface compatibility is not established by the FDA packet.
Clarius's support article on cloud data security says Clarius Cloud data is stored in AWS data centers in a customer-chosen region (Canada, United States Oregon, EU Frankfurt or Australia), exams can be sent to PACS by DICOM with cloud storage disabled, activity logs are kept for six months, patient information is stored for seven years, backups run hourly and are kept 365 days, and an independent third party validates security. No certification is named, and the information security whitepaper it cites was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Clarius' cloud security support article states 6-month log retention, 7-year patient data retention, and hourly backups kept for 365 days for its AWS-hosted cloud, with third-party security validation.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The article names Clarius' cloud generally and does not scope these commitments to any specific product release; exact-release scope is not established. These are logging, retention and backup commitments; the article states no alerting or response-time SLAs.
The FDA packet describes integration with the Clarius App and C3 HD3 or EC7 HD3 Clarius Ultrasound Scanner configurations for B-mode prostate ultrasound.
exact submission · checked 2026-09-14
Confirm current mobile operating-system support, configurations, and downstream interfaces locally.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-14 - Exact FDA submission
No current exact-product price, contract term, or implementation fee was established.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-14 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-14 - Exact FDA submission
Current training, competency, and support commitments require vendor confirmation.
Authorized purpose: SmartTarget is an accessory for image-guided interventional and diagnostic prostate procedures that enhances two-dimensional transrectal ultrasound, reconstructs three-dimensional ultrasound, and displays multiplanar views, annotations, and instrument location for procedures such as biopsy, ablation, and brachytherapy.
Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.